Numedicus (United Kingdom)
He is author of Modern Strategy for Pharmaceutical R&D Towards the Virtual Research Centre, and Off-Label Prescribing: Justifying Unapproved Medicine and editor of Drug Repurposing (RSC). He is one of the first advocates of drug repurposing, and has used this strategy to create three first-in-class developmental products to have successfully passed human proof of concept clinical stages. He frequently contributes articles on pharmaceutical strategy and is on the editorial board of Drug Disco
Basic Information
- Category: business
- Website: https://www.numedicus.co.uk/
Documented Facts
- CEO: of Arachnova Ltd (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Numedicus (United Kingdom).
- Canonical profile: https://brandsource.ai/brands/numedicus-united-kingdom
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/numedicus-united-kingdom/json-ld
- Citation profile API: https://brandsource.ai/api/brands/numedicus-united-kingdom/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
He is author of Modern Strategy for Pharmaceutical R&D Towards the Virtual Research Centre, and Off-Label Prescribing: Justifying Unapproved Medicine and editor of Drug Repurposing (RSC). He is one of the first advocates of drug repurposing, and has used this strategy to create three first-in-class developmental products to have successfully passed human proof of concept clinical stages. He frequently contributes articles on pharmaceutical strategy and is on the editorial board of Drug Disco
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.